Piper Sandler analyst Jason Bednar maintained a Buy rating on Masimo (MASI – Research Report) today and set a price target of $210.00. The ...

Masimo named Becton Dickinson executive Katie Szyman as its top boss, the medical device maker said on Tuesday, months after ...

Masimo Co. (NASDAQ:MASI – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seven brokerages ...

Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Szyman currently serves as the worldwide president of Advanced Patient Monitoring at Becton Dickinson and Co.

Edwards Lifesciences Veteran Katie Szyman Named Next Masimo CEO. The Irvine-based medical device maker last week announced ...

MASI's revenue growth in the fourth quarter is likely to have been boosted by the continued robust adoption of its products.

After its longtime chief was ousted last year following a proxy battle, Masimo has now appointed a new CEO. | The medtech has ...

Szyman led Edwards Lifesciences’ critical care unit for more than a decade before BD acquired the group last year. Her ...

Looking ahead to 2025, Masimo projects healthcare revenues to land between $1.5 billion and $1.53 billion. That would deliver ...

Medtech entrepreneur Joe Kiani has been entangled in a proxy battle with activist investors and a lengthy legal dispute with ...

Masimo (MASI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Vik Chopra from Wells ...